Dario Campana

Professor Campana is the scientific founder of MediSix Therapeutics. An internationally renowned expert in cell therapy, he was the creator of the first anti-CD19-41BB-CD3z CAR that is the key component of Kymriah, the first CAR T-cell therapy approved by the FDA and marketed globally. Currently, Dario is Professor of Pediatrics at the National University of Singapore, and holds the Mrs Lee Kong Chian Chair in Advanced Cellular Therapy.

He is the recipient of consecutive Singapore Translational Research Investigator awards, the Jacob and Louise Gabbay Award in Biotechnology and Medicine and the Republic of Singapore President’s Technology Award. Dario is an elected member of the American Society for Clinical Investigation and the Association of American Physicians. In addition to MediSix, Dario is also the scientific founder of cell therapy start-ups Unum Therapeutics (Cambridge, MA) and Nkarta Therapeutics (San Francisco, CA) and holds several patents.

Dario obtained his MD and PhD in Italy at the University of Torino and the University of Milano, respectively. He trained as a scientist at the Royal Free Hospital, University of London, before moving to St. Jude Children’s Research Hospital in Memphis, where he was Full Member in the Departments of Oncology and Pathology, and Professor of Pediatrics at the University of Tennessee. Dario’s main interest is translational research in oncology, focusing on monitoring response to treatment in leukemia, and on immunotherapy of leukemia, lymphoma and solid tumors.